AACR · Jul 2026
AACR news release summarizing the same prevention study; notes 90% KRAS-specific T-cell response, durable responses over two years, and Adventris-related conflict disclosures.
Adventris makes cancer vaccines
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Adventris Pharmaceuticals is a YC Winter 2023 biotechnology company focused on cancer immunotherapy and cancer vaccines. Public materials describe its lead program as an off-the-shelf KRAS-targeted vaccine for lung/pancreatic cancer, with later updates referring to a next-generation engineered antigen therapeutic (ADV8121) and broader KRAS-driven cancer prevention/treatment goals. Public sources disagree on HQ (San Francisco vs Baltimore), so both are noted in the office location fields. [Adventris site] [YC] [Johns Hopkins] [Nature]
Primary product
Off-the-shelf KRAS-targeted cancer vaccine (mKRAS-VAX / KRAS vaccine platform); next-gen ADV8121 engineered antigen therapeutic
Founded
2022
Headquarters
San Francisco, California, United States (some public directories also list Baltimore, Maryland)
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Open Positions
0 jobs at Adventris Pharmaceuticals
No open positions
Check back later for new openings